Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2222 Biliary Mixed Neuroendocrine-Nonneuroendocrine Neoplasms: A Series of Four Cases with Review of Literature

Introduction: Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs) are rare tumors comprising of both adenocarcinoma and neuroendocrine component, at least 30% of each in the lesion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Pande P

Authors: Pande P, Desai G, Shah R, Palepu J,

Keywords: minen, biliary mixed neuroendocrine-nonneuroendocrine neoplasms,

#1540 FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs)

Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: FOLFOX, tolerability, tumor response.,

#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,

Keywords: pulmonary carcinoids, temozolomide, safety,

#1387 FOLFOX in Neuroendocrine Tumors

Introduction: Favorable toxicity profile and significant antitumor activity of FU-oxaliplatin in several malignancies led us to evaluate FOLFOX in advanced neuroendocrine carcinomas (NETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Faure M

Authors: Faure M, Raoul J, Autret A, Mineur L, Boustany R,

Keywords: Neuroendocrine tumors, folfox, clinical improvement, break in treatment, PFS, OS,

#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET

Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Galli L, Antonuzzo A, Vasile E,

Keywords: capecitabine, oxaliplatine ,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!


The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.